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Abstract
A Kinetic Study of anti-VEGF-A Polyclonal Antibodies
and anti-VEGF-A ssDNA Aptamers
Heather Hedeen
A new detection reagent that could possibly augment or replace
antibodies research and diagnosis methods are aptamers. Aptamers are ssDNA,
RNA or polypeptide constructs that function like active antibodies. Antibodies and
aptamers both specifically bind to selected target molecules, and as such they
enable the detection or targeting of the presence or absence of a specific
antigen.
In order to ensure that ssDNA aptamers perform similarly to antibodies,
anti-VEGF-A polyclonal antibody and anti-VEGF-A ssDNA aptamer were
evaluated against vascular endothelial growth factor A (VEGF-A) using Surface
Plasmon Resonance (SPR). It was hypothesized that the anti-VEGF-A aptamer
had the same, if not better, binding kinetics than the anti-VEGF-A polyclonal
antibody, and as such offers an ideal replacement for use in in field, real-time
testing assays.
SPR revealed that both the polyclonal antibody and ssDNA aptamer
bound the target antigen, VEGF-A. Additionally, from the SPR kinetic analysis,
the anti-VEGF-A aptamer had KD values of 20-28 nM and the anti-VEGF-A
antibody had KD values of 16-127 uM. The binding efficacy of the aptamer was
several orders of magnitude better than that of the antibody. The aptamer was
also stable in solution for a longer amount of time than the antibody, which
denatured in solution after two weeks.
Goals of the thesis:
•

To gain an understanding of SPR instrument use

•

Kinetic analysis of anti-VEGF-A polyclonal antibody

•

Kinetic analysis of anti-VEGF-A ssDNA aptamer

•

Ramifications of kinetic analysis
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I. INTRODUCTION
Biotechnology is a constantly changing field of technical knowledge as
new techniques and materials are researched and developed. What was once
the standard in many areas of research is now giving way to these new methods
and materials that are being created by researchers. Many of these new
techniques allow for novel diagnostic and analysis procedures that are more cost
effective and less time consuming than their predecessors. One such shift is that
from antibodies to aptamers; aptamers offer a new methodology for testing and
identifying selected analytes. Another advancement in detection technology in
the last decade is Surface Plasmon Resonance (SPR), which requires a limited
amount of antigen, even down to the order of femto-moles. However, the lowest
detectable level is often dependent on the amount of background noise created
and varies from experiment to experiment based on the molecules used [1].
The research presented here combines aptamers, antibodies, and SPR
as an analysis technique to support the validity for shifting from antibodies to
aptamers for use as detection reagents on medical and pathological diagnostic
platforms. SPR is used to analyze the similarities or differences in the kinetics
binding between anti-VEGF-A antibodies, anti-VEGF-A aptamers and VEGF-A. It
is hypothesized that that aptamers have similar or better binding kinetics than
antibodies do and as such offer ideal replacements as biotechnology seeks to
produce better in field, real-time testing assays. All together the data gathered
will be used to help develop a proof-of-concept for utilizing aptamers on
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diagnostic paper microfluidic testing platforms as an inexpensive, stable and
reusable platform that may be performed quickly and easily.
These aptamer detection platform assays will not only affect laboratory
techniques but will also allow for the production of rapid in-field testing assays for
use by the FDA, first responders, the HSO, the Navy, and in developing
countries.
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II. BACKGROUND
FUNDAMENTALS OF ANTIBODIES
Structure and function
Antibodies play a crucial role in the immune system; they are naturally
produced by B-cells as part of the humoral immune response to the presence of
foreign antigens within the body. The structure of antibodies has been
determined through X-ray crystallography to consist of three globular regions
assembled into a Y-shape. This Y-shape is composed of two heavy and two light
chains. The heavy chains are linked together by disulfide bonds into the
preliminary Y-shape and the two
light chains are in turn linked to the
heavy chains at the top of the Y by
disulfide bonds. Together the light
and heavy chains make up the
symmetrically identical Y-shaped
antibody structure. Antibodies make
up the most diverse class of proteins
with all antibodies having a constant
c-terminus, at the bottom of the Y–

Figure 1: Basic structure of an antibody.

shape, and a variable n- terminus, found at the top of the Y. The n-terminus
changes for optimal binding to antigens and is unique to each antibody produced.
When antibodies are exposed to pepsin, they cleave into Fab and Fc fragments.
The n-terminus is made up of the Fab fragment; it is composed of a complete
3

light chain and part of the heavy chains on each side. Fab stands for fragments
of antigen binding and is where the antigen interacts and binds to the antibody.
The c-terminus is composed of the Fc fragment, or Fragment crystallizable
fragment, made up by the bottom portion of the heavy chains. The Fc fragment
does not interact with antigen, but instead interacts with cells and effector
molecules. Genetic modification can be used to optimize the Fab and Fc
fragments for binding and interaction between the antibody, antigen and cell
receptors [2]. Antibodies that are produced for research result from two different
production techniques, which produce slightly different antibody products:
monoclonal and polyclonal antibodies.
Monoclonal antibodies
Niels Jerne, Georges Kohler, and Cesar Milstein developed monoclonal
antibody (mAb) production and won the Nobel Prize in Physiology or Medicine in
1984 for their discovery [3]. Monoclonal antibodies are produced from cell lines
created from murine derived cells that have been immunized with the desired
antigen. Cells are either produced through tissue culture or direct injection of
mice from which the mAb will be processed and purified. mAb production in mice
is a commonly used technique that is well understood, their use and well being
must monitored due to Institutional Animal Care and Use Committees. Cell
culture, while becoming more common, is still not as widely understood and
using in vivo techniques and is expensive and time consuming.
mAb production in mice follows five basic steps. Step 1: the mice are
immunized with antigen emulsified Freud’s adjuvant to encourage an immune
4

response and the production of antibodies at the injection site. The mice are
immunized every few weeks in order to obtain the desired antibody titer within
their serum. Step 2: the mice are screened for antibody production by using
blood samples to measure the level of antibodies in their serum. If the titer in a
mouse is too low, then the mouse will be inoculated with more antigen. Once the
titer is high enough in the serum, cell fusion is performed. The mice are injected
with one final antigen dose three days before cell fusion takes place, but at least
two weeks after they received their previous immunization. The mice are
euthanized and their spleen or lymph nodes are removed to produce hybidomas.
Step 3: preparation of myeloma cells for fusion with the antibody-producing cells
from the mice. The antibody-producing cells from the mice have a limited lifetime
whereas the myeloma cells are immortal. When the two cells are combined, they
result in cells that are capable of immortal growth and continued production of
antibody. The myeloma cells are cultured with 8-azaguanine so that they will not
die when exposed to hypoxanthine-aminopterin-thymidine (HAT), which is used
to positively select for only antibody producing cells that have fused with the
myeloma. The myeloma cells also have been modified to lack hypoxanthineguanine phosphoribosyl transferase (HGPRT-), this means that the myeloma
cells cannot synthesize purines and in order to survive they need to fuse with the
normal GHPRT+ mouse cells. Step 4: Fusion of the myeloma and antibodyproducing cells. Fusion between the antibody-producing cells and the myeloma
cells is achieved by co-centrifuging them at a ratio of 10:1 in polyethylene glycol
causing cell membranes to fuse. Since the fusion is random, only some of the
5

fused cells are between the antibody-producing cells and myeloma cells.
Selection for these cells uses HAT media. The aminopterin in the HAT is a folic
acid analogue that blocks the biosynthesis of purines and pyrimidines, ceasing
DNA synthesis. Any antibody-producing/antibody-producing fused cells will not
be able to survive in the HAT media because they cannot synthesize DNA. Any
myeloma/myeloma-fused cells will die in a few weeks because they lack HGPRT.
The antibody-producing/myeloma fused cells will have HGPRT provided by the
antibody-producing cells and the myeloma cells will keep them alive in the HAT
solution. 500 hybrids that are usually made per mouse spleen and only around
20 to 30 of those are usable hybrids. The antibody-producing/myeloma fused
cells are placed into well plates that contain feeder cells, believed to promote the
growth of hybridoma cells through supplying growth factors. Step 5: cloning the
hybridoma cell lines. The hybridoma cells from the well plates are grown in tissue
culture and then selected for based on antigen binding.
After mAbs are developed, they can be produced in vitro using batch
tissue-culture or semipermeable-membrane-based system production if the
specific cell line allows in vitro production. Batch tissue-culture is used to grow
hybridoma cultures in batches from which pure mAb can be extracted. Fetal
bovine serum commonly used as the tissue-culture media however serum-free
media has been developed to avoid possible contamination. Batch tissue-culture
methods are low cost, easy to perform, and only take around 3 weeks to produce
the same quality of mAb as those produced in vivo. However, batch tissueculture does not produce high concentrations of mAb, usually below 20ug/ml.
6

While it easy to perform this method, large amounts must be produced to obtain
usable amounts of antibody. Also, some antibodies denature when they are
purified and concentrated from the culture during batch tissue-culture. Another
option for in vitro production of antibodies is semipermeable-membrane-based
system production. A barrier is used that has a low-molecular-weight cutoff
allowing for cells to grow at high densities; when hybridoma cells grow at higher
densities in culture the result is the production of higher amounts of harvestable
mAb. Semipermeable-membrane based systems make it possible to isolate the
cells and mAb in the chamber separated from the culture media. This allows for
supplementation of growth factors to optimize the growth of the hybridomas and
keeps nutrients for the cells and any undesired cell waste away from the mAb
product through diffusion. Media can be constantly replaced without losing any
cells or mAb contained in the small chamber. Semipermeable-membrane based
systems allow for higher concentrations of mAb to be produced in low volumes of
culture, however, the mAb may be contaminated by any dead cell products that
do not diffuse through the membrane. Semipermeable-membrane-based
systems are more technically difficult to run than batch tissue-culture methods.
These two techniques allow for in vitro options that do not involve euthanizing
animals while still producing functional monoclonal antibodies. The production of
monoclonal antibodies is necessary for the development and production of
diagnostic and therapeutic techniques [4].
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Polyclonal antibodies
Polyclonal antibodies differ from monoclonal antibodies by recognizing
multiple binding sites for one antigen, meaning that there is a heterogeneous
mixture of antibodies all with different affinities for the antigen within one sample.
This causes polyclonal antibodies to be prone to variability between batches,
unlike monoclonal, which are identical between batches. One reason that
polyclonal antibodies can be more desirable than monoclonal antibodies is
because monoclonal antibodies may be too specific to detect an antigen if any
mutation has occurred [5]. Polyclonal antibody production is similar to
monoclonal antibody production in that a laboratory animal is used, however,
various animals may be selected depending on the amount of serum needed and
how easily it can be obtained. Some animal choices include mice, chickens,
guinea pigs, goats, and sheep. Antigen is injected subcutaneously,
intramuscularly, intradermaly, or intraperitonealy in several sites on the animal
along with an optional adjuvant, to promote the immune response at the injection
site. Blood is taken from the animal, up to 10% of the blood volume of the animal
at a time every 3 to 4 weeks from which the antibody is harvested [6]. The blood
is centrifuged to separate the red blood cells from the serum. An antigen-bound
sepharose bead column can be used to separate the desired antibodies from the
other antibodies in the serum solution. The serum is run through the column and
only the desired antibodies will bind to the antigen-bound beads and all the
others will run through. The bound antibodies are then eluted from the sepharose
beads and collected as polyclonal antibodies that all bind to the same antigen.
8

Use in research
Antibodies are used for many different applications including diagnostic
analysis and disease targeting. Antibodies can be used as drugs with specific
targeting; monoclonal antibodies are used to make cancer cells more visible to
the immune system by attaching to parts of the cancer cells and alerting the
immune system to attack it. Antibodies can also be used to block growth signals,
stop new blood vessels formation, or deliver radiation to specific cancer cells [8].
One of the most common techniques involving antibodies is ELISA, which
is used for determining the presence or absence of diseases such as HIV. ELISA
(enzyme-linked immunosorbent assay) can be performed several ways, all
involving the use of antibodies. Firstly, indirect ELISA is performed when the
target antigen is adsorbed to the bottom of the wells on a plate and antibodies
extracted from a patient are allowed to interact with it. Finally anti-human
antibodies are used to image the plate to determine if there was binding between
the patient antibodies and the antigen. If binding occurs then the individual has
that antigen present in body. Indirect ELISA is performed to determine whether
an antigen is present or not, the second ELISA technique allows for detection
and quantification of the antigen. The second most common form of ELISA is
sandwich ELISA. Sandwich ELISA is performed by adsorbing anti-antigen
antibodies to the bottom of the wells on a plate. The sample from the patient is
then added to the wells to allow interaction with the antibody. Next, another
antibody is added that will also bind to the antigen. Finally an enzyme linked
antibody is added that will interact with the second antibody, the enzyme will
9

produce a detectable signal that will allow for the quantification of antigen present
[9].
Western blot also utilizes antibodies; specific proteins may be identified
within the gel through modified antibodies that allow for imaging. Proteins are
separated by size using SDS-PAGE and then electrophoresis is used to transfer
them to nitrocellulose paper. A process similar to that in ELISA is used where the
proteins are incubated with primary antibody and then secondary antibodies that
allows for visualization and quantification of the amount of protein.
A relatively new technique for antibody use are microarrays where
anywhere between 5,000-10,000 proteins can be analyzed at a time. Proteins
are captured on the chip by specific primary antibodies and then analyzed using
secondary imaging antibodies. These imaging antibodies are often recombinant
antibodies that allow for detection by fluorescence, nano-electrodes, and surface
plasmon resonance [10]. This technique is most commonly used for overall
proteomic analysis.
Antibodies are also used for in-field testing that has the advantage of
being quick, easy to perform, with easily interpreted results. One such test is the
pregnancy blood test. hCG is present in the blood of pregnant women, an
immobilized primary capture antibody is used to bind to this molecule and a
secondary signal antibody is then used to give a response. One important thing
to note for test like this is the possibility of false positives due to interfering
antibody interaction. This interaction occurs if the Fab regions on the interfering
antibody interact with those on the primary and secondary antibodies. This will
10

cause the signaling antibody to indicate a positive, even though no antigen is
present. Another diagnostic test that has been developed using antibodies are
blood typing kits. Antibodies are immobilized to the surface of the testing kit,
when blood interacts with the antibodies it will coagulate if antigen is present.
Based on which antibodies the blood coagulates with both the blood type and the
Rhesus factor can be determined.
As more selective and stable binding between antibodies and antigen are
required, new antibodies modifications are being developed in the laboratory to
meet these needs. The Fab segments of antibodies have been mutated in order
to manufacture antibodies with higher affinity binding. This is achieved by
improving the contact and molecular interactions between the antibody and the
antigen [11].
Advantages/disadvantages
There are many different reasons for selecting between monoclonal and
polyclonal antibodies when performing an experiment. Polyclonal antibodies are
selected for use when an increased signal is desired since there are various
antibodies that all bind to the same antigen at different sites. Polyclonal
antibodies are also less sensitive towards changes in the antigen allowing for
detection of any mutated antigen. Monoclonal antibodies, on the other hand, are
selected when highly specific binding is needed between antibody and antigen.
Since mAbs are produced by hybridomas more quantity can be produced of
identical and pure antibodies. However, polyclonal antibodies are much less
expensive to produce than monoclonal antibodies and require a lower level of
11

technology and skill. Polyclonal antibodies also take significantly less time to
produce than monoclonal antibodies do.
There are also advantages and disadvantages to utilizing antibodies
instead of other molecules. Antibodies cannot easily be produced for toxins due
to the fact that they are produced in animals that cannot tolerate them long
enough to produce an antibody for them. Another restriction of antibodies since
they are produced to function in cells is that for diagnostic techniques, antibodies
are often not able to function in non-physiological conditions. Since antibodies
have complex, protein based structures they are denatured easily due to
temperature, susceptible to oxidation or deamidation, degradation or
aggregation, leading to a limited shelf life.

FUNDAMENTALS OF APTAMERS
Production
Aptamers are produced through a method called the SELEX (systematic
evolution of ligands by exponential enrichment) process. This process begins
with a random sequence oligonucleotide library that is obtained by combining the
four nucleotide building blocks, adenine, thymine, guanine, and cytosine for DNA
and adenine, cytosine, guanine, and uracil for RNA. Depending on if a RNA or
DNA aptamer is being created, the specific four nucleic acids molecules are
added together in a concentration based on the coupling efficiency of each
individual monomer. A fixed sequence is used as a primer for binding
amplification of the oligonucleotide sequences. The length of nucleotide positions
in the random region determines how complex the oligonucleotide library will be;
12

for example, if a library has a “40-nucleotide random region” the library will
contain up to 1.2X1024 different sequences. However, a library is typically limited
by chemical synthesis to only contain around 1014-1015 sequences [12].
Once a random library is synthesized, it is exposed to the target of interest
for which the aptamer is being designed. The target of interest is bound to
nitrocellulose paper prior to being exposed to the oligonucleotide sequences so
that all non-binding sequences can then be washed off, leaving the bound
sequences to attached to the target on the nitrocellulose paper. Once the
unbound sequences are washed off, the bound sequences are eluted and
amplified using PCR for creating a DNA aptamer or RT-PCR for an RNA
aptamer. The binding and amplification process is repeated in order to increase
the affinity for the bound molecules. Typically around 8-15 cycles of affinity
enrichment are performed, taking around 2-3 months to produce high affinity
binding aptamers. The SELEX process creates aptamers that over 90% of the
time are able to bind to the target and are around 70-80 nucleotides in length
[12]. These sequences can be paired down from the 70-80 nucleotide length to
cut out any areas that do not play an important role in the three dimensional
structure of the aptamer for binding with the target molecule.
After aptamers are fully developed through the SELEX process, they can
be produced in less than 3 days, resulting in identical product each time. Another
step may be added to the SELEX process resulting in counter-SELEX where
aptamers can be counter selected for. This comes in useful when creating an
aptamer that will bind to a cell, but only those that display a particular
13

characteristic, such as being infected with cancer. Counter-SELEX is
accomplished by eliminating any oligonucleotides that have affinity for motifs
present on non-targeted cells.
Structure
Aptamers are composed of either ssDNA or RNA that are usually 70-80
nucleotides in length. The aptamer folds into a three dimensional structure that
will interact with the antigen of choice, much like an antibody does. The molecule
that interacts with the aptamer is called a ligand and aptamers are designed to
specifically bind to one and only one ligand.
RNA structure is determined by the primary, secondary, and tertiary
interaction that it undergoes. Primary structure is determined by the nucleotide
sequence that makes up the RNA strand. The secondary structure of the RNA is
determined by the two-dimensional interactions between the individual
nucleotides that make up the RNA. For RNA common secondary structures are
duplexes, single-stranded regions,
hairpins, bulges, internal loops, and
junctions (Figure 2) [13]. The tertiary
structure of RNA is determined by the
interactions between the different regions
of the two-dimensional secondary
structures of the RNA strand that make
up the three-dimensional shape of the
molecule. Some examples of common

Figure 2: RNA Secondary Structures
Some of the common two-dimensional
secondary structures of RNA. (Figure from
Batey, Robert T. et al.)
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tertiary interactions are triple interactions: the RNA single strands interact with
double-stranded RNA complexes through hydrogen bonding, pseudoknots: form
where the RNA nucleotides in a hairpin loop pairs with a single stranded region
of RNA, kissing hairpins: formed when unpaired nucleotides from one hairpin
loop interacts with another unpaired nucleotide in another loop [14].
The structure of RNA allows for reversible denaturation, meaning that the
tertiary and secondary structures are no longer formed when the RNA molecule
is exposed to an atmosphere that facilitates denaturation. Once the denaturing
climate is removed, the RNA will fold back into its original form with the
secondary and tertiary structures (Figure 3). One issue with RNA aptamers in

Figure 3: Reversible denaturation pathway of RNA
On the far right the RNA is completely denatured, slowly the secondary structures resulting from
the interactions between the nucleotides are achieved. Finally on the far left the tertiary structures
are completed, resulting in the three-dimensional shape of the RNA. (Figure from Batey, Robert T.
et al.)

regard to their structure is the ability of nucleases to degrade the RNA; therefore
modifications have been developed to protect the RNA aptamers. Modifications
have be made to the 2’ position on the pyrimidine nucleotides by adding –F or NH2 functional groups to prevent denaturation by nucleases.
Another solution to the degradation of RNA aptamers is to use a single
stranded DNA aptamer instead. Single stranded DNA (ssDNA) acts much like
RNA in that it is able to interact with itself to form into two and three-dimensional
shapes through interactions. ssDNA will form secondary structures just like the
15

RNA aptamers: internal loops, hairpin loops, bulges, dangling ends, terminal
mismatches, coaxial stacking, and multibranched loops [15]. It has been
suggested that ssDNA tertiary structure is based on the guanine quadriplex
structure, which is part of the secondary aptamer structure and is made up of
one, two, or four oligonucleotide strands [16]. DNA aptamers are also suspected
to have a partially disordered tertiary structure when no antigen is bound [17].
Furthermore, in a thrombin aptamer study, it was indicated that due to the fact
that the tertiary structure of aptamers is highly specific, is very important for the
binding interaction with the ligand [18].
Modifications are often made to the structures of both RNA and ssDNA
aptamers in order to increase their usefulness in laboratory techniques or to
increase stability. The increase in RNA stability has already been discussed; this
is achieved through producing the aptamers from libraries that contain the
modified pyridinines instead of normal ones. Other modifications that have been
developed are made at the C-5 position on the pyrimidines and include the
addition of –I or –Br for photo or chemical crosslinking, -SH for chemical
crosslinking, and amino acid side chains for chemical dressing [12]. 3’-end caps
have also been added to aptamers in order to reverse their polarity, and as such
preventing any 3’ exonuclease activity. PEG is also added to the 5’ end of
aptamers to extend the in vivo half-life of aptamers [19]. One interesting result of
modification is that the primary and secondary structures of the aptamers are
significantly changed from those produced without the modifications.
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Use in Research
The structure of aptamers allows them to bind to target molecules or cells
with high affinity and specificity. Aptamers have so far been developed for targets
such as metal ions, organic dyes, drugs, amino acids, co-factors,
aminoglycosides, antibiotics, nucleotides, and peptides [12]. One specific use for
aptamers is their utilization for lead detection in the environment; gold
nanoparticles are coated with engineered molecules made up of a 12-mer
aptamer, a DNAzyme, and a substrate. In the absence of lead, the substrate
hybridizes with the aptamer causing the gold to aggregate, resulting in a blue
color. If lead is present, then the DNAsyme catalyzes hydrolytic cleavage of the
substrate so that the aptamer is no longer able to bind. This prevents the
aggregation of the gold and produces a red color. UV-vis spectroscopy is used to
detect these color changes as well as to quantify the amount of Pb2+ present in
the sample [20].
Aptamers have also been modified using Photo-SELEX to create
aptamers that are capable of simultaneous quantification. During the SELEX
process modified nucleotides are used that can be activated by the absorption of
light. Aptamers made up of these nucleotides covalently bond with their target
when activated by light, leading to greater sensitivity and specificity. Chips have
been made using Photo-SELEX-evolved aptamers that are incubated with
extremely dilute sample and can allow for imaging and quantification of the
sample [21].
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Counter-SELEX has already been used to develop an aptamer against
glioblastomas, one of the most common brain cancers. Aptamers such as this
can be used as molecular probes for the detection, characterization, and isolation
of tumor cells when they have been modified with fluorescent labels. Aptamers
have successfully been used to target and identify cells within bone-marrow
aspirates [22].
Aptamers have also been developed as drugs that target specific
molecules. In 2004, Macugen was developed and approved by the FDA as a
drug against age-related macular degeneration. As of 2012, Macugen is still the
only aptamer based therapeutic that has been approved for market by the FDA.
Macugen is an RNA aptamer the binds to all isoforms of VEGF. There have
been other attempts to develop antigen-based drugs such as an antidotecontrolled anticoagulant RNA aptamer. This aptamer drug functions by using an
aptamer that elicits an anticoagulant effect by binding and inhibiting the activity of
coagulation factors. A complimentary aptamer region was also developed that
upon injection binds and neutralizes the active form of the drug. The drug went to
phase 1 of clinical trials but the study was terminated because the protocol
defined safe threshold was exceeded in one subject who received the highest
dosage [23].
Aptamers have also been used in techniques such as flow cytometry and
immunosensors, taking the place antibodies. Aptamers are showing promise to
be used as sensors based on electrochemical detection; since aptamers are
polyanionic they can be used to sense changes in conduction based on the
18

presence or absence of a target molecule. One study used this technique to
develop a microfluidic electrochemical aptameric assay integrated on a chip that
was able to detect selected targets in a mixed sample with no interference [24].
Other areas of research where aptamers have begun to take hold are as
molecular switches, for detection of proteins (being referred to as “Eastern
blotting” completing the blotting technique quadruple), aptamer arrays for
proteomic analysis, and many other clinical applications for disease drug
analysis.
Advantages/disadvantages
Aptamers offer an alternative to traditional molecular choices such as
antibodies. Aptamers offer an advantage over antibodies because they can be
created for any molecule, even those that are toxic to biological systems.
Aptamers also allow for a plethora of modification options, from making them
more detectable to changing the kinetic on- and off-rates, something much more
difficult to do with antibodies [12]. Aptamers offer high reproducibility, meaning
that there is little to no batch-to-batch variability. Due to the nature of RNA and
ssDNA, aptamers are able to undergo reversible denaturation. This reversible
denaturation holds one of the highest advantages of aptamers over antibodies as
it offers for production of reusable diagnostic testing platforms, further lowering
the cost of production. Products such as this would be ideal for in field-testing;
especially in third world countries where clinical analysis is difficult and cost is a
huge factor. Aptamers are also much more cost effective to produce than
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monoclonal antibodies are, taking around the same amount of time with little to
no hands-on interactions needed and less experienced lab technicians required.
So far one of the only major limitations that has become apparent for
aptamers is the vulnerability of RNA aptamers, but the aptamer may be modified
as talked about previously to compensate for this. SELEX can also be laborious
to carry out, however, automated systems now exist that are faster and more
economical that require little to no human intervention that can run multiple
SELEX experiments at a time.
Another current disadvantage to the use of aptamers is the fact that their
invention was still less than 20 years ago so many of the applications and
production techniques related to aptamers are still protected under patents.
Gilead Science acquired many of the patents that are related to the SELEX
process as well as the actual aptamer structures that have been produced [25].
The length of patent protection is 20 years after filing takes place so the first of
their patents, filed in 1992 will expire this year along with several other patents in
the coming years. Archemix is another company that has intellectual property
rights to aptamers, specifically to the exclusivity to use of them in therapeutic
applications [25]. The first of their patents was filed in 2002 so their patents will
not begin to expire until 2022. However, they have licensed out the rights of their
patents to several other companies to use in the research and develop other
therapeutic applications. SomaLogic has exclusivity to the use of aptamers for
diagnostic applications [25], with their first patent filed in 1999 and expiring in
2019. Since many of the patents initially filed that relate to aptamers are starting
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to expire, there is a high likelihood that new applications for aptamers will
continue to be developed in upcoming years that involve previously patent
protected techniques.
An alternative to both aptamers and antibodies that are also being
researched are molecular imprinted polymers (MIP). A MIP is a polymer that is
made using a three dimensional template that is then removed, leaving behind a
three-dimensional polymer with complimentary spaces from where the template
was removed. Unlike both aptamers and antibodies, MIPs are made of entirely
synthetic products making them even more stable than aptamers are with the
ability to withstand high temperatures, pH ranges, and long-term storage. MIPs
have the ability to recognize and bind to specific target molecules and offer
another option besides antibodies and aptamers that have to for use in many
techniques that currently employ antibodies [25].

FUNDAMENTALS OF SURFACE PLASMON RESONANCE (SPR)
Surface Plasmon Resonance History and Theory
R.W. Wood first discovered the theory behind surface plasmon resonance
in the early twentieth century with his work on diffraction on diffraction gratings
due to the excitement of surface plasmon waves. Kretschmann and Otto
continued to research surface plasmons through optical excitation in the 1960s.
Since 1992 the amount of research publications that mention the use of SPR has
exponentially grown each year from only a handful in 1992 to over 500 in the first
half of 2006 [26].
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Surface resonance is a charge-density oscillation that occurs at the
interface of two media that have opposing dielectric constants [27]. This
oscillation results in a surface plasmon wave. Surface plasmon waves are TMpolarized waves, meaning that the magnetic vector is perpendicular to the
direction of the propagation and parallel to the plane of the interface. Surface
plasmons are the collective oscillations made by the free electrons in a metallic
film. When exposed to specific conditions, the surface bound plasmons will
resonate with light, resulting in the absorption of the light. These conditions are
extremely sensitive with respect to the refractive index of the medium that is
located adjacent to the metallic film, which means that the presence of any
molecules on or near the surface of the film can easily be detected.
One common method used to excite the surface plasmons into their
resonance oscillations is the Kretschmann configuration that uses a p-polarized
laser and a metal film, typically gold or silver. The incident angle reflection of the
laser on the metal film is used to achieve the resonance of the surface plasmons.
When the incident angle is small and resonance is occurring, the incident light
may be absorbed by the metal film resulting in a low intensity of reflection. This
means that the reflected light remains at
a high intensity for a large range of
angles except at the resonance angle.
In order to find the resonance angle, θR,
Equation 1 is used. ε1 can be water, air,
or a variety of other solvents or

Equation 1: SPR resonance angle
Used to calculate the resonance angle, θR.
ε2 is the dielectric constant of the prism, εm
is the real part of the dielectric constant of
the metal film, ε1 is the dielectric constant of
the testing medium to which the metal film
faces.
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solutions, often for biological SPR experiments PBS buffer is used. A shift in θR
occurs then there are molecules near or on the surface of the metal film. The
shift in the resonance angle is proportional to the amount of molecules that are
adsorbed on the metal film surface, through observing the changes in the
resonance angle it is possible to measure the association, disassociation, and
affinity binding constants for the molecules [27].
SPR Components and System
BIAcore AB released the first commercially available SPR system in 1990
and since then several other companies have also developed and released
commercial SPR systems. Each SPR machines, no matter which company
produced it, has the same basic components and systems as they all perform
analysis using the same basic theory.
The main difference between SPR systems is how automated they are
and how many analysis channel
exist; these two components
both directly relate to the cost of
the SPR system. The main
components in all systems are
the flow cell through which the
sample and running buffer flow.
There is a prism (Figure 4) on
which the metal film chip is
placed, often with a specific

Figure 4: Surface Plasmon Resonance
Shows the interaction of the molecules and their
effect on the metal film surface and the resulting shift
in reflected light from the laser. This shift is translated
to graphical data allowing for analysis of the kinetic
interactions on the molecules. (Figure from B!-2000
SPR Manual v5.4)
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molecule, the ligand, immobilized on the surface. The binding or interacting
molecule to the ligand is injected into the buffer solution as it flows across the
surface of the functionalized metal chip surface. As the ligand and its conjugate
interact the refractive index will change, this change is measured and imputed
into the system’s software that analyses it and shows the mDeg change in the
angle of refraction. This information can be further analyzed to give the kinetic
data for the interaction between the ligand and the interacting molecule [29].
Due to the sensitivity of SPR, all liquids that are run though the system
must be either sonicated or degassed to remove any dissolved gas molecules in
the solution. When injecting samples into the machine care must be taken to
avoid gas bubbles in the injection syringe as well. Dissolved gasses in the
solution will result in random spikes in the sensorgram that will interfere with the
results. Care must also be taken when cleaning and preparing the prism surface
before placing the chip on it. If the prism is scratched at all, the refraction angle
will not be able to properly observe molecular interactions taking place. The flow
rate of the buffer should not exceed 150uL/min or there is not enough time for the
kinetic or equilibrium constants to be extracted from the flow data [28]. The flow
rate cannot be too slow either or mass transport limited kinetics will occur [28].
Use in research
SPR has been used in several areas of research including for the
measurement of physical quantities of materials, for chemical sensing analysis,
and for biosensing analysis. SPR was first used in 1983 for biosensing analysis,
and in 1994 the first real-time biospecific interaction analysis was developed [27].
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SPR provides detection and analysis for chemical, biochemical, and biological
substances in the areas of medicine, environmental analysis, and drug and food
safety. One advantage of using SPR is that it is a label-free process that still
allows for the analysis between molecules. Another huge benefit of using SPR in
analysis is that only a very small amount of sample is required and machines
offer real-time analysis and the use of multi-channels for the analysis of
simultaneous samples.
SPR has been utilized to perform microscopy as SPRM or SPR imagine
(SPRI). SPRI allows for the measurement of DNA and RNA binding to DNA
arrays or DNA-binding proteins to dsDNA arrays, proteins to protein and peptide
arrays, and ligands to protein arrays. SPRI can determine the on- and off-rates
and the equilibrium binding constants for all of these interactions simultaneously,
sometimes on the order of more than 1,000 at a time. This technique offers cost
and time efficient detection and analysis technique [30]. SPRI is accomplished by
spotting probe molecules onto the analysis surface, this must be done in a way
that will not denature or inactivate the probe, will enable the probe to survive
washing for multiple use, and makes the probe available for other molecules to
interact and bind to. There are many different methods and materials that have
been developed to functionalize the surface of SPR chips.
The first method that is commonly used to attach molecules to the surface
of SPR chips is through thiol-linking the molecule directly onto the gold metal
film. Attachment of molecules to the gold surface through thol-linking is achieved
by exposing the gold surface to thiol-alkane linked molecules and allowing
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chemisorption to occur; this binding is vey stable and allows for complex media
buffers to be used [31]. Another common immobilization method is achieved by
using carboxymethyl dextran (CM-Dextran) that forms a self-assembled
monolayer (SAM) onto which other molecules can easily be bound. An activating
kit is used to activate the dextran surface and allows for amine coupling occurring
between the dextran particles and the molecules will become immobilized on the
surface. Other chemical attachments and surface modifications that are used
include aldehyde coupling, streptavidin-biotin linking, silicate and silicon
functionalized surfaces, and biocoatings [32].
SPR has become a common laboratory technique to observe the binding
kinetics between modified antibodies and aptamers and the ligands they were
created to bind to. The VEGF-binding affinities for the Fab fragments of
antibodies were observed in an experiment that was attempting to select for
optimized binding in a modified anti-VEGF antibody [33]. Similarly SPR was used
when screening for an improved anti-VEGF DNA aptamer. Using SPR not only
allowed for kinetic analysis of the binding between the aptamer and VEGF, but it
was also used to observe the role that KCl played in the three-dimensional shape
of the aptamer [34].
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III. MATERIALS AND METHODS
SPR CALIBRATION AND TECHNIQUE
The SPR instrument must be calibrated every couple months in order to
align the signals given by each microfluidic channel so that they are identical.
This calibration was done using a 1% ethanol solution and by comparing the
measured mDeg response
in each channel to the
expected response

Equation 2: SPR calibration
Used to calculate the new values to calibrate the channels
in the SPR machine.

changes using Equation 2.
Gloves were worn for the entire experiment to avoid contamination of the
machine and exposure to the solutions. The 1% ethanol solution was made by
adding 0.1mL of 99% EtOH to 10mL of DI H2O, both the EtOH and DI H2O were
previously degassed for an hour in a bell jar apparatus to remove any dissolved
gases in the solution. The SPR machine was then prepared for use. Two 10mL
syringes were filled with the DI H2O as running buffer and placed in the Syringe
Cradle and fastened with the Retainer Bar. The Drive Bar was adjusted to just
barely touch the end of both syringes. Finally the syringes were screwed into the
flow tubing.
Next the prism surface was prepared for a new chip. There was an old
chip still on the prism surface that was maneuvered using a cotton swap so that
the prism was not scratched and then tweezers were used to fully remove the
chip. To clean the prism surface 99% EtOH and cotton swabs were used. The
cotton swab was soaked in EtOH and then moved in a spiral pattern around the
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prism surface starting in the middle and working outwards. This process was
repeated until the prism surface was completely clean. The Flow Cell channels
were also cleaned using EtOH and cotton swabs. Mounting the SPR chips on the
prism was achieved by placing a small drop of index matching oil in the center of
the prism. The drop should be only 3-5uL or it can leak out from under the chip
and contaminate the experimental results. To ensure the drop was the right size,
the initial few drops of oil were dabbed off onto the rim in the bottle and then the
glass transfer rod was lightly placed above the prism until as small drop was left
on the prism. The chip was inspected to determine which side was gold and
which side was glass, this was achieved by lightly scratching the edge of both
sides of the chip. The gold side of chip showed scratch marks and the glass side
did not, the chip was then placed on top of the prism. To ensure no gas bubbles
were trapped between the chip and the prism, one side of the chip was placed
down before the other using tweezers. A cotton swab was then used to move the
chip around slightly. The Flow Cell was then moved into place on top of the chip.
The machines were then turned on and the flow rate of the running buffer was
set to 150uL/min to force out any trapped air bubble in the tubing. After ~5
minutes the flow rate was reduced to 50uL/min and the laser was turned on. To
make sure that there were no air bubbles in the flow cell there is a viewing
window that should show two similar SPR dark lines about 4mm wide each. This
was observed and the machine was allowed to warm up for around 30 minutes,
until signals in both channel 1 and channel 2 were flat.
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The calibration was then performed. The machine was placed into serial
mode. The default calibration value is 3,000; this value was used as an initial
calibration to run the first 1% ethanol injection. The expected mDeg result was
supposed to be 60. The injection was made using a 200uL syringe and injecting
around 150uL of sample into the Injection Valve. The valve was then turned to
the ‘Injection’ position until the countdown on the computer reached 15 seconds
left out of 96, when it was switched back to ‘Load.’ After each injection of 1%
ethanol Equation 2 and the mDeg measuring software was used to find the
adjusted calibration value for each channel until they both were 60mDeg.
In order to get a feel using the instrument and the software an additional
ethanol dilution experiment was performed after the machine was calibrated. Two
additional solutions of ethanol were made along with the 1% ethanol solution: a
0.25% solution and a 0.0625% solution. The 0.25% solution was made by
pipetting 1mL of the 1% ethanol solution into 3.01mL of DI H20 and the 0.0625%
solution was made by pipetting 1mL of the 0.25% solution into 3.0025mL of DI
H20. These solutions were injected into the machine the same way as the 1%
ethanol solution was and the results were saved so that they could be analyzed
using the kinetic software.

SELECTION OF CARBOXYMETHYL DEXTRAN
Carboxymethyl Dextran (CM-Dextran) is a polyanionic derivative of
Dextran. Dextran is composed of α (16) linked glycan that has side chains
attached to the 3- positions of the backbone glucose units [35]. CM-Dextran
allows for molecules to be immobilized on its surface though amine coupling. The
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CM-Dextran chips were ordered from Biosensing Instrument and stored at -20°C.
Activation kits for the CM-Dextran Sensor Chips were also ordered from
Biosensing Instrument and stored at -20°C as well.

USE OF VEGF
VEGF-A is a member of the PDGF/VEGF growth factor family and codes
or a protein that acts on endothelial cells with various effects. Some of these
effects include: increased vascular permeability, induction of angiogenesis,
vasculargenesis, promotion of cell migration, and inhibition of apoptosis [36].
VEGF-A was one of the molecules for which both aptamers and
antibodies have been developed, making it a perfect molecule for comparing the
kinetic interactions between it and both its aptamer and antibody conjugates.
The VEGF-A, also known as VEGF 165, was ordered from Syd Labs as
recombinant human VEGF 165. This molecule was produced in HEK 293 derived
cells and had a molecular weight of 19.2kDa. The stability of the VEGF-A was for
12 months if stored as -20°C to -70°C in evaporated form, 1 month after
reconstitution if stored at 2°C to 8°C in sterile conditions and for 3 months after
reconstitution of stored at -20°C to -70°C under sterile conditions [37].
The VEGF was diluted to a 25nM solution, a 50nM solution, and a 150nM
solution. 10.417mL of DI H2O was added to the 10ugram of VEGF sample to
create a 50nM stock solution. The 50nM solution was then diluted to half by
adding 1M PBS buffer to create the 25nM solution. The 150nM solution was
produced by adding 2uL of 1.5mg/mL VEGF solution to 1037.67uL of 1M PBS
buffer.
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IMMOBILIZATION OF VEGF AND ANTIBODY/APTAMER INTERACTIONS
VEGF-A was immobilized to the CM-Dextran surface in order to observe
the kinetic interactions between it and the anti-VEGF aptamer and anti-VEGF
antibody. The solutions were made at a concentration of between 25 and 100nM
due to the fact that the SPR machine is extremely sensitive to samples and only
a small amount is required. Typically concentrations used for immobilization are
between 10-100nM.
Antibody Solution
The anti-VEGF-A antibody was ordered from Bioss and was a rabbit antiVEGF-A polyclonal unconjugated antibody. The antibody was stored at -20°C, a
temperature where it would be stable for at least one year. The anti-VEGF-A
antibody solution was prepared in three concentrations: 100nM, 50nM, and
25nM. The 100nM solution was made by pipetting 2222.22uL of DI H2O with
100ugram of the anti-VEGF antibody. The 50nM concentration was made by
pipetting 1mL of the 100nM solution into 1.5mL of DI H2O. The 25nM solution
was made by pipetting 1mL of the100nM solution into 3mL of DI H2O. Once
reconstituted, the antibody was stored at 2-4°C, a temperature where it was
stable for at least two weeks [38].
Aptamer Solution
The anti-VEGF-A aptamer sequence was taken from Nonaka et al. from
when they searched for an improved anti-VEGF-A DNA aptamer. The sequence
of the aptamer from the 5’ to 3’ end was 28mers long:
GCACTCTGTGGGGGTGGACGGGCCGGGT; it was ordered from Eurofins and
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stored at -20°C .The aptamer was unconjugated with no modifications and
already in a reconstituted solution of 43.79ug/uL. Three concentrations of the
anti-VEGF-A DNA aptamer were made: 100nM, 50nM, and 25nM. The 100nM
solution was made by pipetting 1uL of the 43.79ug/uL solution into 48.996mL of
DI H2O. . The 50nM concentration was made by pipetting 1mL of the 100nM
solution into 1.5mL of DI H2O. The 25nM solution was made by pipetting 1mL of
the100nM solution into 3mL of DI H2O. The solutions were stored at 2-4°C.
pH of VEGF-A Solution
The pH of the VEGF turned out to be an important factor for the
immobilization of the VEGF onto the CM-Dextran. Initially after the 50nM VEGFA solution was mixed the pH was ~7.0. However due to the isoelectric point of
both the VGEF-A and the CM-Dextran, at this pH the VEGF-A was not able to
immobilize on the CM-Dextran surface. Ueda et al. performed an experiment
with VEGF-A and used a pH of 4.5 [39], so the pH of the solution was adjusted
accordingly. A 20mM solution of HCl was made to adjust the pH of the VEGF-A
solution as well as a pH probe. To make the 20mM HCl solution 10uL of 6M HCl
was added to 2990uL of DI H2O. Initially this process was carefully calculated out
but the 1M PBS buffer resisted the change in pH so much more HCl had to be
added to reach the desired pH. The pH of both the 25nM and 150nM VEGF-A
solutions were adjusted to ~4.5.
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Other solutions
To regenerate the surface of the VEGF-A functionalized CM-Dextran chip
a 20mM solution of NaOH was used. A 1M NaOH solution made by adding 1
gram NaOH to 1L DI H2O; this solution was then diluted down to 20mM.

EXPERIMENTS
Before any experimental SPR runs were carried out all solutions utilized
were degassed for 1-2 hours to remove any dissolved gases in the solutions. The
machine was also cleaned and prepared with the same steps as in the 1%
ethanol calibration experiment. CM-Dextran chips were used and 1M PBS
running buffer. The flow rate of each experiment varied.
Run 1
The first SPR run used the pH ~7.0 50nM VEGF-A solution, and the antiVEGF-A antibody solutions and the anti-VEGF-A DNA aptamer solutions. The
surface of the CM-Dextran was prepared for immobilization by using an
activation kit bought from Biosensing Instrument. For this run all activation
solutions were mixed before degassing took place. A 0.1M Nhydroxysulfosuccinimide (NHS) solution was made by adding 0.5mL DI H2O to
the provided vial. A 0.4M 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC)
solution was made by adding 0.5mL DI H2O to the provided vial. A 1.0M Ethanol
Amine (EA) solution was also made by adding 1mL of DI H2O to the provided
vial. After all solutions were degassed and the SPR machine was loaded with
running buffer and a new CM-Dextran chip and completely warmed up the CMDextran chip was activated and the VEGF-A was immobilized. The flow rate of
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the running buffer was set to 30uL/min. The 0.1M NHS and 0.4 M EDC were
mixed together and immediately 100uL were injected into the flow to activate the
CM-Dextran surface. Immediately after the activation signal finished, the 50nM
VEGF-A solution was injected followed by the 1M EA solution in order to block
the CM-Dextran surface. This whole process was performed in serial mode. The
order of the injections was: 50nM antibody, NaOH, 50nM aptamer, NaOH,
100nM antibody, NaOH, 25nM antibody, NaOH, 50nM antibody,
Run 2
To help the VEGF-A immobilize to the CM-Dextran surface the pH of the
VEGF-A solution was changed to 9. The isoelectric point of VEGF-A was either
8.5 [40] or 9.22 [41] so a pH between the two was chosen. The surface of the
CM-Dextran was prepared for immobilization by using the activation kit bought
from Biosensing Instrument. For this run the activation solutions were mixed after
degassing took place and immediately before injection into the machine. Once
the NHS/EDC solution was used to activate the CM-Dextran solution, the 25nM
VEGF-A solution at pH 9 was injected a few times. The order of the injections
was: 50nM antibody, NaOH, 50nM aptamer, NaOH, 100nM antibody, NaOH,
25nM antibody, NaOH, 50nM antibody, NaOH, 100nM antibody, NaOH, 100nM
antibody. All injections after immobilization took
Run 3
The third SPR run used the pH ~4.5 25nM VEGF-A solution, and the antiVEGF-A antibody solutions and the anti-VEGF-A DNA aptamer solutions. The
surface of the CM-Dextran was prepared for immobilization by using the
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activation kit bought from Biosensing Instrument. For this run all activation
solutions were mixed after degassing took place. The CM-Dextran surface was
activated with NHS/EDC solution and then three injections of VEGF-A at pH 4.5
and one injection of VEGF-A at 9.3 were run. The CM-Dextran chip was then
blocked using the EA solution. The order of the injections was: 50nM antibody,
NaOH, 50nM antibody, 50nM antibody, NaOH, 100nM antibody, NaOH, 100nM
aptamer, NaOH, 50nM aptamer, NaOH, 25nM antibody, NaOH. After the final
NaOH a few other injections were carried out but they were distorted by an air
bubble in the system and therefore discounted. All injections after immobilization
took place were performed in single mode.
Run 4
Since the prior SPR run did not allow for the kinetic analysis software to
be used another SPR run was performed. In order to quantify the data the two
channels had to be calibrated to give the same singles, this was achieved
through using a 0.5M PBS buffer solution and Equation 2. The average in the
initial channel readings was taken and used as the expected value. Once the
calibration was finished the CM-Dextran surface was activated with NHS/EDC
solution and three injections of pH 4.5 25nM VEGF-A was injected. After
immobilization of VEGF-A, EA was injected to block the CM-Dextran. Only
channel 2 was immobilized with VEGF-A using single mode injections. NaOH
was injected to remove any remaining VEGF-A molecules and then the machine
was switched to serial mode and the sample injections were made. The order of

35

the injections was: 100nM antibody, NaOH, 100nM antibody, NaOH, 100nM
aptamer, NaOH, and 100nM aptamer.
Run 5
Since the antibody did not work in run 4, the SPR run was a fifth time. A
0.5M PBS buffer calibration was done for the new dextran chip before
immobilization took place. The surface of the CM-Dextran chip was activated with
NHS/EDC solution and the pH ~4.5 150nM VEGF-A solution was injected four
times in single mode into channel 2. The EA solution was then injected to block
the CM-Dextran and NaOH was used to wash away any remaining VEGF-A
molecules. The order of the injections was: 100nM aptamer, NaOH, NaOH,
100nM antibody, NaOH, 80nM antibody, and NaOH. At this point an air bubble
disrupted the experiment to the point it could not be continued.

ANALYSIS SOFTWARE
The BI-Data Program allows for analysis of the results recorded by the
computer during the SPR runs. Selected data is transferred from the BI-Control
to the data analysis program where several steps were performed with it. The
program can zero the data responses, crop data, align curves, subtract reference
responses, and calculate the kinetics of the data. First the curves to be analyzed
were selected, one as reference (the channel where no VEGF-A was
immobilized) and another (the channel where the VEGF-A was immobilized).
The data was then zeroed to align the curves and cropped to the area of interest.
Next the reference channel was subtracted from the other channel to give the
actual interaction curve between the VEGF-A and the anti-VEGF-A antibody and
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anti-VEGF-A aptamer. Next the kinetic analysis was used to fit a curve to the
data from which km, ka, and kd were calculated, as well as Rmax. For the ethanol
dilutions an additional step was added that allowed for an affinity curve to be
calculated using the various concentrations.
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IV. RESULTS
ETHANOL DILUTIONS
The ethanol dilutions were used to both calibrate the SPR machine and to
get a feel for the experimental
process and analysis software.
Figure 5 shows the relationship
between each of the ethanol
dilutions. The mDeg difference
for the 1% ethanol solution was
used in the calibration of
channels by being fit to a 60mDeg
curve. The 0.25% ethanol solution

Figure 5: Ethanol dilutions
Shows the ethanol dilutions from left to right: 1%,
0.25%, 0.25%, 0.0625% and, 0.0625%.

when measured in both channel one and channel two was equal to ~15.41mDeg.
The 0.0625% ethanol solution had a change of 4.2mDeg when averaged across
the two channels.
These three concentration curves were put into the software analysis
program and the kinetics and affinity relationships between the ethanol and the
gold surface of the chip were calculated two ways. The program was first used to
find the kinetics: a line was fit to the binding curve from which the binding affinity
(KD), dissociation rate constant (kd), association rate constant (ka), maximum
response (Rmax), and mass transport coefficient (km) are calculated (Figure 6).
KD = 29.701mM. Rmax = 2,395.5. ka = 53.15. kd = 1.579. km = 8881.8. The second
method used the affinity analysis to find the KD based on the steady state of each
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Figure 6: SPR analysis fit curves
Shows the fit of the curve to the ethanol
concentrations, those for 1% and 0.25% are
much better than for 0.0625%. From these
curves the kinetic binding between the gold
and the ethanol can be determined.

Figure 7: Affinity of ligand curve
Shows the affinity curve between the
ethanol and the gold chip surface,
calculated using the concentrations of the
ethanol.

curve between the different calibrations (Figure 7). From this method KD =
29.2mM. Rmax = 2300.1.

RUN 1
The first SPR run for analysis of the kinetics between the VEGF-A and the
anti-VEGF-A antibody and anti-VEGF-A aptamer (Figure 8). There was no
binding between the molecules observed. The large downward curve was
caused by the bulk flow of the liquid in the injected sample, the portion were the
binding would have occurred is the bottom of the curve. If interaction had

Figure 8: Attempted immobilization of VEGF-A
Shows the activation of the CM-Dextran surface with NHS/EDC solution, the injection of
the 50nM VEGF-A solution, and the deactivation of the surface with EA.
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Figure 9: Absence of VEGF-A binding between antibody and aptamer
Shows an excerpt of the inaction curves between the VEGF-A and the anti-VEGF aptamer
and the anti-VEGF-A antibody. Since the bottom of the curve is flat, no binding took place.

occurred, there would have been a slight increase in the line, however it was flat
for all sample injections, the NaOH, and even DI H2O (Figure 9).

RUN 2
The second SPR run was changed from the first by adjusting the pH of the
VEGF-A solution from ~7.0 to ~9.0. Even with this adjustment the VEGF-A did
not immobilize onto the CM-Dextran surface (Figure 10). The VEGF-A upon
injection had no interaction with the surface.

Figure 10: Failed immobilization of VEGF-A
Shows the activation of the CM-Dextran surface, however, the VEGF-A was not immobilize
onto the surface, evidenced by the lack of an upward signal when the VEGF-A was injected.

RUN 3
The third SPR run adjusted the pH of the VEGF-A again, this time to ~4.5.
The VEGF-A was successfully immobilized onto the CM-Dextran as seen by the
slight upward curve in the SPR signal after the initial bulk flow curve of the fluid
(Figure 11). Due to the fact that channel 1 and channel 2 were not correctly
calibrated, the kinetics on the molecular binding could not be analyzed. However
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a qualitative analysis of the
binding curves may be
done. Using the computer
the mDeg change in each
curve was measured
(Figure 12).

Figure 11: Successful immobilization of VEGF-A
Shows the immobilization of the VEGF-A onto the CMDextran. The large downward curve is caused by the
bulk flow of the fluid in the sample since it is not the
same as the running buffer. The immobilization of the
VEGF-A is seen by the slight upward curve magnified

b
.

a
.

Figure 12: Quantitative kinetic analysis of antibody and aptamer
a. Shows the binding curve between the anti-VEGF-A antibody and the VEGF-A. b. Shows the
binding curve between the anti-VEGF-A aptamer and the VEGF-A. These curves simply show
there was binding between the molecules.

RUN 4
The fourth SPR run was performed to obtain data that would allow for
quantitative kinetic analysis (Figure 13). A gold chip was used to obtain a new
calibration where channel 1 = 2034.93 and channel 2= 2090.77 (Table 1). Using
the new calibrations 0.5M PBS buffer
was used to calibrate the CMDextran chip using the same
mathematical process. The initial
mDeg reading in channel 1 was
158.160 and in channel 2 was

Figure 13: PBS buffer calibration
Shows the overall SPR run from calibration
to injections of the antibody and aptamer.

184.557. The average was taken to find the ‘ideal’ number from which both
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Channel 1

3000(60/89.143)=
2019.23

2019.23(60/59.537)=
2034.93

Channel 2

3000(60/85.815)=
2097.54

2097.54 (60/61.667)= 2040.83(60/56.280)=
2040.83
2175.73

Table 1: PBS calibration calculations
Shows the calibrations calculations for 1% ethanol to reach 60mDeg change
in both channel 1 and channel 2. Once calibrated the channels can be used
for quantitative data where one channel is a reference to subtract out bulk
flow interference.

channels were to be calibrated: average = 171.359. The same calibrate
mathematical process was carried out as with the 1% ethanol and channel 1=
2171.73 and channel 2= 1966.89. The surface appeared to be functionalized,
giving a curve similar to Graph 7. Once the injections of anti-VEGF-A antibody
and anti-VEGF-A aptamer were completed the kinetic analysis program was
used to analyze the data. Channel 2 was where the VEGF-A was immobilized
and channel 1 was used for the reference, the data was imputed into the
program (Figure 14). The curve was zeroed to align the baselines of both
channel 1 and channel 2 (Figure 15).Excess data was removed using the
cropping page in the software. The date was then aligned. The reference,

a.

Figure 14: Step 1 of kinetic analysis
Data is input into program in order to
determine the binding interactions
between the VEGF-A and the antiVEGF-A ssDNA aptamer.

b.

Figure 15: Step 2 of the kinetic analysis
The program zeros the curves so that they
can be directly compared. a. Shows the
graph before zeroing took place. b. Shows
the graph after it is zeroed.
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a.

b.

Figure 16: Step 5 of kinetic analysis
Program subtracted the reference channel from
the channel where the VEGF-A was
immobilized. a. Shows the graph before it is
referenced. b. Shows the graph after it is
referenced, can finally see the binding curve
between the VEGF-A and the anti-VEGF-A
DNA aptamer.

Figure 17: Kinetic curve of aptamer
Step 6 of the kinetic analysis program fits
a line to the binding curve. From this
curve the km, ka, kd, Rmax, and KD are
calculated.

channel 1, was subtracted from channel 2
to reveal the actual binding interaction
curve between VEGF-A and anti-VEGF-A
aptamer (Figure 16). A curve was fit to the
curve from which the kinetic data was found
(Figure 17). From the data obtained,
analyzed, and averaged: KD= 24.1nM, km=

Figure 18: Curve of denatured antibody
Shows the fitted line to the binding curve
of the interaction between the antiVEGF-A and VEGF-A.

1.76X108, ka= 1.02X1011, kd= 2549, and Rmax=56.7 (Table 2). The 100nM
antibody was also analyzed using the kinetic software (Figure 18).

Table 2: Aptamer Kinetics
Shows the results of the kinetic analysis software for the anti-VEGF-A aptamer.
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RUN 5
Run 5 was done to analyze the kinetics of the anti-VEGF-A antibody, all of
the same steps were performed as with
the aptamer until the software fitted a
line to the binding curve (Figure 19).
This graph was used to find the kinetic
properties between the VEGF-A and the
anti-VEGF-A antibody: KD= 88.4uM, km=
8

5

2.16X10 , ka= 1.75X10 , kd= 14.78, and

Figure 19: Kinetic curve of antibody
Shows the fitted line to the binding curve of
the interaction between the anti-VEGF-A
and VEGF-A.

Rmax=74,617 (Table 3).

Table 3: Antibody kinetics
Shows the results of the kinetic analysis of the anti-VEGF-A antibody.
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V. DISCUSSION
ETHANOL
The 1% ethanol gave a measurement of 60mDeg after several calibrations
of both channel 1 and channel 2. The 0.25% ethanol was ¼ the concentration of
the 1% ethanol so it was expected to give a response of 15mDeg. The actual
response was ~15.41mDeg which was very close to the expected. The 0.0625%
ethanol solution was ¼ of the 0.25% and 1/16 of the 1% solution, so the
expected mDeg response was 3.75. The actual results were ~4.2mDeg. This
difference was later explained by the fact that the micropipette used in the
mixture of the 0.0625% solution was not correctly calibrated, causing the solution
to be more concentrated that it should have been. It is possible to tell that the
solution was more and not less concentrated than it should have been because
the mDeg change was greater than it should have been and not less.
The calibration and dilution experiment was important because the
instructions and results were clearly given the BI-2000 Manual and therefore it
was easy to tell if the experiment had been performed correctly through use of
the SPR machine. This was an essential step to know before moving onto the
more complicated experiments where the materials used were much more
expensive. Mistakes such as the calibration of the micropipette were found prior
to the following experiments and new one was ordered. Several other SPR runs
were done using gold chips and ethanol for further experience with the
equipment and techniques such as the correct amount of immersion oil to be
used were learned.
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The ethanol dilution experiment also allowed for the kinetic analysis
software to be used, when unfamiliar with the steps of the program it is confusing
and the results do not make sense. Using the ethanol dilutions allowed for
analysis using both the affinity and the kinetic portions of the software. From the
affinity analysis it was found that KD = 29.2mM and Rmax = 2300.1. When using
the kinetic analysis it was found that KD = 29.701mM, Rmax = 2,395.5, ka = 53.15,
kd = 1.579, and km = 8881.8. While the kinetic analysis results in more data, it is
possible to compare the KD and Rmax directly between the two methods both of
which were very close between the two. The differences between these two
techniques was that the affinity analysis required the use of multiple dilutions of a
sample and then the software was used to compare the steady-state binding at
each concentration. The kinetic analysis requires only one sample with a known
concentration to be used and provides more information. Ideally both methods
would be used for every experiment since the results for each can be used to
verify each other.
The KD≈ 29mM means that there is weak binding between the gold
surface and the ethanol, most likely due only hydrogen bonding between the two
as the ethanol is adsorbed to the gold surface as the fluid travels over it. Ideally
for the binding between a target molecule and its binder, the KD should be as
small of a number as possible. For something such as the interaction between
streptavidin and biotin the KD is on the order of fM [42], which is equal to 10-15M.
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VEGF-A AND ANTI-VEGF-A POLYCLONAL ANTIBODIES SSDNA APTAMER
Run 1
The first SPR run using CM-Dextran and VEGF-A resulted in no
immobilization of the VEGF-A and therefore not interaction between it and the
anti-VEGF-A aptamer or anti-VEGF-A polyclonal antibody solutions. This was
determined by the fact that there was not positive interaction curve when the
antibody or aptamer were injected into the 1M PBS buffer flow. The aptamer and
antibody curves were identical, both showing the same downward bulk flow and
not interaction between the VEGF-A molecules. The Biosensing Instruments
technical expert was contacted and the negative results were verified it was
suggested that the VEGF-A was not able to immobilize in the CM-Dextran due to
the pH of the solution [43]. The technical specialist at Biosensing Instruments
recommended that the experiment be performed within a pH ±1 from the
isoelectric point of the protein. The isoelectric point of VEGF-A was found to be
either 8.5 or 9.2 so the pH of 9 was decided to be used since it was between the
two pHs.
Anther change that was suggested by the technical specialist was to use
the same solution as the buffer for that which the VEGF-A was in to decrease the
downward bulk flow curve. Since the entire VEGF-A sample was already diluted
to 50nM in DI H2O, the sample was further diluted to 25nM. In completely
optimized SPR runs using immobilized proteins concentrations as low at 10nM
have been used for immobilization so the decrease in concentration has
precedent. However, since the VEGF-A experiment could not be optimized as it
47

would use too many materials and therefore cost too much, a higher
concentration was suggested. In order to compensate for the use of only a 25nM
solution of VEGF-A, multiple injections of samples were to be used to increase
the possible amount of protein that could be immobilized.
It was determined that both the CM-Dextran chips and the chemicals in
the activation kit were still viable, an important determination since the CMDextran chips were labeled ‘for best use’ before February and the experiment
was being run in early April.
Run 2
Changing the pH of the VEGF-A solution from ~7.0 to 9.0 did not result in
the immobilization of the VEGF-A into the CM-Dextran on the chip surface. When
immobilizing a protein on the surface of CM-Dextran it is important to take into
consideration not only the isoelectric point of the protein but of the CM-Dextran.
When the pH of a solution containing a protein is less than the isoelectric of the
protein the net charge of the protein is positive and when the pH is greater than
the isoelectric point of the protein the net charge will be negative. This is
important because the CM-Dextran surface is negative when the pH of the
solution is greater than 3.5, in order for the VEGF-A protein to be able to
immobilize on the surface the pH should be higher than 3.5 but lower that the
isoelectric point of the VEGF-A. In run 2, where the pH was 9.0, if the protein had
the isoelectric point of 8.5, that meant that it had a negative net charge and the
CM-Dextran had a negative net charge. This would result in the repulsion of the
VEGF-A from the surface of the CM-Dextran, inhibiting immobilization (Figure
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20). Using this
information, a new
pH of ~4.5 was
selected for the
VEGF-A solution to
complement
immobilization.

Figure 20: Immobilization of CM-Dextran
Shows the attraction or repulsion between a protein and the CMDextran surface depending on the pH of the solution. (Provided
courtesy of GE Healthcare)

Run 3
In run 3, immobilization of the VEGF-A occurred, indicating that the pH of
the VEGF-A solution was the problem inhibiting immobilization in run 1 and run 2.
This immobilization was verified by the upward binding curve after the initial
downward bulk flow of the VEGF-A solution was injected into the 1M PBS buffer
flow. Due to the 25nM concentration three injections of the VEGF-A were used.
In order to prove binding, an injection of pH 9.3 VEGF-A was also used, that did
not immobilize. Due to the fact that the injections were only done in one channel,
only a qualitative analysis could be done between the aptamer and the antibody.
Using this initial analysis between the 50nM antibody and 50nM aptamer
solutions: the kon for the appeared to higher than that of the antibody. The
aptamer also appears to have a slightly better affinity for the VEGF-A than the
antibody does because there was a larger mDeg change, indicating a higher KD.
From the graphs it was not possible to analyze the koff differences between the
antibody and the aptamer. To obtain qualitative differences between the antiVEGF-A antibody and the anti-VEGF-A aptamer the SPR experiment had to be
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run again using a fully calibrated machine and using one channel as a reference
to subtract the bulk flow from the actual interaction curve.
Run 4
The technical specialist at Biosensing Instruments was consulted on how
to calibrate the SPR machine for CM-Dextran chips verse gold chips: using the
initial calibration numbers obtained using a normal gold chip, a 50% dilution of
the running buffer should be used to further calibrate the CM-Dextran chip. Since
a 1M PBS buffer was being used as the running buffer, a 0.5M PBS solution was
used to calibrate for the specific CM-Dextran chip. This calibration was
necessary because in order to use the kinetic analysis software, channel 1 and
channel 2 need to give the exact same readings. This way, any differences
between the two can be detected. This is achieved by immobilizing only one
channel with the VEGF-A, that way only one channel will bind the anti-VEGF-A
antibody or aptamer and the other channel will only show the interaction of the
anti-VEGF-A antibody or aptamer with the surface of the CM-Dextran and any
other bulk flow characteristics. When using a reference channel it is difficult to
see any difference in the curve between the channel with the immobilized VEGFA and that without. It is not until the data is manipulated using the kinetic analysis
software that the binding curve becomes apparent. Each of the 100nM antiVEGF-A aptamer curves were put into the program so that an average of the
interactions could be taken to get more accurate results.
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After the data was zeroed, aligned, cropped, and the reference channel
subtracted a line was fit from which the software was able to calculate KD=
24.1nM, km= 1.76X108, ka= 1.02X1011, kd= 2549, and Rmax=56.7. The KD from the
literature where the anti-VEGF-A aptamer was taken was equal to 20nM, so the
KD found was very close. This difference could be explained by fact that the
VEGF-A used in this experiment had a different source than that used in the
literature. The VEGF-A used in this experiment came from HKE 293 derived
cells. It was also composed of only amino acid 27-191 of the whole sequence
that normally makes up VEGF-A. The VEGF-A used in the literature came from
Sf21 insect cells and there was no data given for if it was composed of the whole
polypeptide sequence. If any of the missing amino acids composed portions of
the VEGF-A to where the aptamer bound, that would explain the change from
20nM to 24.1nM. Either way since the equilibrium dissociation constant (KD) was
in the nanomolar region, that means that the affinity between the VEGF-A and
anti-VEGF-A aptamer was very good. Typically the equilibrium dissociation
constant is between 1X10-5 and 1X10-12. The association rate constant, ka, as
suggested in the
qualitative SPR run, at
1.02X1011 M-1s-1 is very
high. The association
rate constant is how well
the VEGF-A and

Figure 21: Kinetic equilibrium
Shows the relationship between the VEGF-A (B) and the antiVEGF-A aptamer (A). The equation is for calculating the
association rate constant and the dissociation rate constants.
(Provided courtesy of GE Healthcare)

aptamer recognize each
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other. Typical association rate constants are between 1X10-3 and 1X107 M-1s-1.
The dissociation rate constant at 2549 s-1 is much less than the association rate
constant and it shows how stable the binding between the VEGF-A and the
aptamer was. Typical dissociation rate constants are between 1X10-1 and 5X10-6
s-1. This suggests that the binding between the VEGF-A and the aptamer is not
very stable, however the extremely high association constant overcomes this and
still allows for an overall high equilibrium dissociation constant. Rmax at 56.7
means maximum binding capacity and represents the total concentration of
VEGF-A protein immobilized on the CM-Dextran chip.
When the anti-VEGF-A antibody was analyzed it was found that it had
denatured and was no longer binding to the VEGF-A. This makes sense because
the antibody solution was being stored at between 2°C and 8°C and on the
manufacture’s information sheet at that temperature the antibody was only viable
for around two weeks. This experiment was performed roughly 3 weeks after the
solution was made. Luckily, some of the 100nM antibody solution was being
stored at -20°C, where it is stable for up to a year. However, this shows one of
the limitations between using antibodies instead of aptamers, the aptamer was
still stable even after three weeks of storage at a higher temperature. In some
places where temperature control is not easily available this could be a huge
incentive to use aptamers over antibodies. In order to determine exactly how
much longer aptamers last than antibodies additional testing would be required
for this particular antibody/aptamer grouping.
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Run 5
Since the antibody used in run 4 had denatured, another SPR run was
performed to get usable data for direct comparison between the antibody and the
aptamer. In order to ensure that the VEGF-A was still viable and that there was
enough for the anti-VEGF-A antibody to bind to the 150nM solution was used.
Using this concentration would provide ample binding sites to analyze the
antibody; even at this concentration 4 injections of the VEGF-A were made. This
precaution was also taken because the antibody had been giving another
researcher problems with ability to bind with the VEGF-A. The results found were
that KD= 88.4uM, km= 2.16X108, ka= 1.75X105, kd= -14.78, and Rmax=74,617. The
Rmax, is noticeably higher than that with the aptamer, this is due to the use of the
150nM VEGF-A solution instead of the 25nM solution as over 1000 times the
amount of VEGF-A was immobilized on the CM-Dextran surface. The KD at
88.4uM has a magnitude of 1000 times less affinity for VEGF-A than the antiVEGF-A aptamer. The association rate constant at 1.75X105 M-1s-1 for the antiVEGF-A antibody was also significantly less than that of the aptamer, meaning
that the antibody did not recognize the VEGF-A as well. The kd for the antibody
was 14.17 s-1 meaning that the stability between the VEGF-A and the anti-VEGFA antibody was higher than that between the VEGF-A and the aptamer, though
still not low enough to truly be stable.
Antibody verses aptamer
Figure 22 shows the difference between high-affinity and lower-affinity
curves. The anti-VEGF-A aptamer follow the high-affinity curve with a high ka and
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a high kd. The anti-VEGF-A
antibody follows the loweraffinity curve by having both a
low ka and a low kd. Therefore
the aptamer had the overall
highest affinity for the VEGF-A
by a significant amount making
it the better option between the
two based on binding affinities.

Figure 22: High and low affinity curves
The upper curve shows a high-affinity curve where
ka is high and kd is high. The lower curve shows a
lower-affinity curve where ka is low and kd is high. A
high ka means there is fast association and a high kd
means there is fast dissociation. (From Bio Rad
“Protein Interaction Analysis”)

While in this experiment the aptamer had a much higher affinity for the
VEGF-A in some literature there have been antibodies modified to have affinities
less than 1nM [33]. One possible reason that the affinity between the VEGF-A
and the anti-VEGF-A antibody was so poor was because it was a polyclonal
antibody solution; while the antibodies were created for VEGF-A there was no
screening method to select for high affinity binding antibodies in the solution. As
seen in Table 3, the KD is much lower in the 80nM solution that it was in the
100nM solution; perhaps this was because the 80nM solution had more
antibodies with higher affinity for the VEGF-A than were in the 100nM solution.
Ideally for direct comparison between aptamers and antibodies, a
SPR for analysis
SPR offers many advantages for protein and analyte binding analysis.
When compared to techniques such as ELISA and RIA (relative affinity index),
SPR offs a much quicker methodology. In addition, there are no other laboratory
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techniques that offer the same level of kinetic analysis. Traditionally
spectrophotometers have been used to observe kinetics but not in the same realtime way. The fact that only uL of sample is required at concentrations in the nM
range means that this method can be used for analyzing costly materials without
high cost.
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VI. CONCLUSION
Depending on what function the antibody or aptamer is to be used for will
depend on which should be used, however, aptamers have the same function
ability as antibodies do while offering easier modifications and more stability.
Antibodies have long been limited by the fact that they need to maintain
conditions similar to those within the body. Temperature it one of the main
methods through which antibodies are irreversibly denatured; this comes into
paly when being used for diagnostic applications, for example, pregnancy tests
have a shelf life of 12-24 months when stored at room temperature (between 2°C
and 30°C). If a test is being created for in the field testing in a country with
temperatures continually above 30°C where there is limited access to
refrigeration then antibody assays are not going to function for their entire shelf
life. Aptamers on the other hand can be regenerated from their denatured form
and are stable in long-term storage and allow for transportation in various
temperatures [45]. The temperature of denaturation for nucleic acid sequences
depends on what order the nucleic acids is in, since aptamers that are
engineered for a specific molecule can have different sequences, the one with
the most stability in high temperatures can be selected in order to optimize it.
Another advantage of aptamers over antibodies is that they can be
created to molecules that are toxic to cells. This allows for applications of the
aptamer to be expanded beyond that of antibodies to testing devices for toxic
chemicals within the environment. Antibodies during their production cannot be
produced to something that will kill the cell or animal it is being produced in, since
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aptamers are produced in the lab without the use of cells they do not face this
problem. Labeled aptamers could be used to determine the purity of a water
sample by creating a group of aptamers that testing for certain bacteria, heavy
metals or other contaminants and that will activate if bound.
Due to the high level of modifications for aptamers, they offer to be and
ideal molecules for cell targeting. The process of Counter-SELEX has already
been used to develop aptamers that will target only cells with cancer, while
leaving alone those that are healthy. Since aptamers can be modified, there is
potential for them to be used for targeted drug delivery of chemotherapy to
cancerous cells, eliminating many of the negative side effects that accompany
the traditional use of chemotherapy. A similar application of aptamers could
result in the targeting of HIV infected cells and destroying them before spread to
other T cells and the patient advances to AIDS. Another application would be to
use differently labeled aptamers that bind to different types of cells for use in
surgery, by creating differently fluoresced aptamers for different cell types it
would be possible to avoid certain cell types, such as nerves to reduce damage
to the body.
Future research that could apply the information learned about the kinetics
of the anti-VEGF-A antibody and anti-VEGF-A aptamer. For example, lateral flow
immunological assays could be developed using the aptamer, since its affinity is
significantly better than the antibody. Monoclonal antibodies and MIPs should
also be analyzed using SPR in order to directly compare with the results already
obtained. Once all this information is ascertained, the molecules with the best
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binding could be used to create a portable, stable, and quick diagnostic assay.
Similar testing could also be used to select for the best molecule choice in other
diagnostics besides with VEGF-A.
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APPENDIX
A. CALCULATIONS

Molecular weights for all
materials

Calculations for the NaOH solution

Calculation for the 150nM VEGF solution

Calculation for the 100nM antibody solution

Calculation for the 100nM aptamer solution
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Calculation for the 50nM solutions

Calculation for the 25nM solutions

Calculation for the HCl solution

Calculations for attempting to change the pH to 8.6, the PBS buffer resisted
the change of pH so pH was changed using a pH probe
63

B. SPR ETHANOL RAW DATA

Overall ethanol dilution experiment

mDeg of the 1% ethanol solution
64

mDeg of the 0.25% ethanol solution

mDeg of the 0.0625% ethanol solution
65

Ethanol curves input into the BI-Analysis program

Zeroing page of the ethanol analysis
66

Cropping page of the ethanol analysis

Alignment page of the ethanol analysis
67

Analyte bound page of the ethanol analysis

Affinity page of the ethanol analysis
68

Kinetics page of the ethanol analysis page 1

Kinetics page of the ethanol analysis page 2
69

C. SPR RUN 1 RAW DATA

Activation of CM-Dextran and attempted immobilization of VEGF-A

Overall injections of sample for Run 1 page 1
70

Overall injections of sample for Run 1 page 2

71

D. SPR RUN 2 RAW DATA

Activation of CM-Dextran surface and attempted immobilization of
VEGF-A

72

E. SPR RUN 3 RAW DATA

Overall SPR Run 3

Immobilization of VEGF-A
73

Run 3 injections page 1

Run 3 injections page 2
74

Run 3 injections page 3

100nM antibody qualitative analysis
75

100nM aptamer qualitative analysis

50nM antibody qualitative analysis
76

50nM aptamer qualitative analysis

25nM antibody qualitative analysis
77

25nM aptamer qualitative analysis

78

F. SPR RUN 4 RAW DATA

Overall SPR Run 4

Activation of the CM-Dextran and immobilization of VEGF-A
79

VEGF-A immobilization curve

Run 4 Injections
80

100nM binding curve

100nM aptamer kinetic analysis page 1
81

100nM aptamer kinetic analysis page 2

100nM aptamer kinetic analysis page 3
82

100nM aptamer kinetic analysis page 4

100nM aptamer kinetic analysis page 5
83

100nM aptamer kinetic analysis page 6

100nM aptamer kinetic analysis 2
84

G. SPR RUN 5 RAW DATA

Overall SPR Run 5

Run 5 injections page 1
85

Run 5 injections page 2

100nM antibody binding curve
86

Selection of the curve to be analyzed and the reference to be

100nM antibody kinetic analysis page 1
87

100nM antibody kinetic analysis page 2

100nM antibody kinetic analysis page 3
88

100nM antibody kinetic analysis page 4

100nM antibody kinetic analysis page 5
89

100nM antibody kinetic analysis page 6

100nM antibody kinetic analysis page 7
90

100nM antibody kinetic analysis 2
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H. VEGF INFORMATION SHEET

92

I. ANTIBODY INFORMATION SHEET

93

94

95

J. BI ANALYSIS SOFTWARE PROTOCOL
All data is from ethanol dilutions experiment from protocol except for Step 2 and
Step 7.
Step 1: Open raw date curves from
experiment. (Figure 1)

Figure 1

Step 2: Select curve and reference
curve. (Figure 2)

Figure 2

Step 3: Enter concentrations of solutions
injected. For example: if 30nM solution
was used, enter 30n. For example, if 3
dilutions were made, enter concentration
into ‘Bulk conc’ and then the dilution
factor, and then 1, 2, 3 for each
concurrent dilution: bulk concentration
=1% (0.01) and dilutions of 1/4 are made,
enter 1 for 1% and 2 for 1/4 dilution and 3
for 1/16. (Figure 3)
Figure 3
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Step 4: Zero the data by placing the
green and then red lines over an area of
the curve that is flat for each curve.
(Figure 4)

Figure 4

Step 5: Crop the data to remove excess
from each side by moving the green line
to crop at the beginning and the red line
to crop at the end. (Figure 5)

Figure 5

Step 6: Align the data by placing the
green line at the beginning of the first
curve and the red line at the peak of the
last curve to remove any variation in time
due to channels. (Figure 6)

Figure 6
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Step 7: Subtract the reference channel
from the channel where sample was
bound (channel 1-channel 2 or channel 2channel 1). (Figure 7)

Figure 7

Step 8: Bound ligand is calculated by
placing the green and red lines where
each curve is at steady state. (Figure 8)

Figure 8

Step 9: Computer calculates the affinity,
KD and Rmaz. Also shows the curve of
bound ligand at steady state verses the
concentration. (Figure 9)

Figure 9
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Step 10: Fit the orange lines to the data
curves and the kinetic data KD, ka, kd,
Rmac, km are calculated. How well the line
fits the curve is shown by either a red or
green bar above the results. The green
line is placed where the curve begins ad
the red line is placed where the steady
state ends and the curve drops back
down. (Figure 10)

Figure 10

Step 11: Can then view all results on the Results pag

99

100

